南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停

Hesperetin与铂类药物联合增强肺腺癌抗癌效果的研究

Combination of hesperetin and platinum enhances anticancer effect on lung adenocarcinoma

Yadong Wang, Shaorui Liu, Wei Dong, Xiao Qu, Cuicui Huang, Tao Yan, Jiajun Du

Journal:BIOMEDICINE & PHARMACOTHERAPY

IF:3.74

DOI:10.1016/j.biopha.2019.108779

PMID:30889488

Published:2019-03-16

research field:肿瘤学细胞生物学生物化学

Abstract

Lung cancer remains the leading cause of oncological death. There is an urgent need to discover new molecular targets and to develop new treatments. One of the UDP-glucuronosyltransferases (UGTs) family, UGT1A3, is highly expressed in lung adenocarcinoma (LUAD), and is associated with poor prognosis. Its inhibitor, hesperetin, may play an important role in anticancer therapy. The purpose of this study was to investigate the role of UGT1A3 in the progression of lung adenocarcinoma and to explore the value of its inhibitor hesperetin in the treatment of LUAD. Hesperetin suppressed lung adenocarcinoma cell proliferation and migration. The combination treatment of hesperetin with platinum suppressed tumor progression more significantly, especially compared with single drug treatment. UGT1A3 is an important prognostic factor for LUAD, and hesperetin can synergize platinum drugs by inhibiting UGT1A3 and increasing levels of reactive oxygen species (ROS).

本文使用的Yeasen产品

购物车
客服
转染试用